Overview

Safety and Efficacy in Adult Subjects With Acute Migraines

Status:
Completed
Trial end date:
2018-01-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the efficacy of BHV-3000 (rimegepant) versus placebo in subjects with Acute Migraines
Phase:
Phase 3
Details
Lead Sponsor:
Biohaven Pharmaceutical Holding Company Ltd.
Biohaven Pharmaceuticals, Inc.